Finanzen von Anbio Biotechnology (NNNN)NNNNAnbio Biotechnology

Evaluating the bottom line, Anbio Biotechnology maintains a gross margin of 87.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 66.70%, while the net margin is 74.06%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively NNNN converts its operational activities into shareholder value.

In the context of the broader market, NNNN competes directly with industry leaders such as MYGN and TCMD. With a market capitalization of $536.71M, it holds a significant position in the sector. When comparing efficiency, NNNN's gross margin of 87.24% stands against MYGN's 66.60% and TCMD's 75.50%. Such benchmarking helps identify whether Anbio Biotechnology is trading at a premium or discount relative to its financial performance.

Anbio Biotechnology has a gross margin of 92.32% projected for Q2 2025, which is exceptionally high and suggests strong profitability. The current ratio is also very healthy at 211.10, indicating good short-term financial health.